camptothecin
Camptothecin (CPT) is a topoisomerase inhibitor. It was discovered in 1966 by M. E. Wall and M. C. Wani in systematic screening of natural products for anticancer drugs. It was isolated from the bark of Camptotheca acuminata, a tree native to China used in traditional Chinese medicine. It has been used clinically in China for the treatment of gastrointestinal tumors. CPT showed anticancer activity in preliminary clinical trials, especially against breast, ovarian, colon, lung, and stomach cancers. However, it has low solubility and adverse effects have been reported when used therapeutically, so synthetic and medicinal chemists have developed numerous syntheses of camptothecin and various derivatives to increase the benefits of the chemical, with good results. Four CPT analogues have been approved and are used in cancer chemotherapy today: topotecan, irinotecan, belotecan, and trastuzumab deruxtecan. Camptothecin has also been found in other plants including Chonemorpha fragrans. — Wikipedia
Clinical trial activity
11 trials · 20 clinical orgs · 0 marketing orgs
Earliest trial started Jul 8, 2002 (NCT00040989)
Timeline
Indications
Studied for
Mechanism of action
- Topoisomerase IINHIBITOR
Topoisomerase I inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCamptothecin ↗
Also known as
- 20-o-(nalpha-(4-(3-o-methylfucopyranosyloxy)phenylaminothiocarbonyl)histidylvalyl)camptothecin
- 20-o-(nalpha-(4-(3-o-methylfucopyranosyloxy)phenylaminothiocarbonyl)histidylvalyl)camptothecin hydrochloride
- 20(s)-camptothecin
- 20(s)-camptothecin
- 21,22-secocamptothecin-21-oic acid lactone
- 21,22-secocamptothecin-21-oic acid lactone
- bay383441
- bay 383441
- bay 38-3441
- bay-383441
- bay-38-3441
- bay 56-3722
- bay 56-3722
- camptothecin
- camptothecin
- camptothecin
- (+)-camptothecin
- (+)-camptothecin
- ct2106
- ct 2106
- ct-2106
- ct-2106
- polyglutamate camptothecin
- polyglutamate camptothecin
- poly-l-glutamate camptothecin
- tlc 388
- tlc 388
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05411679 | Phase 2 | Apr 30, 2023 | Ellipses Pharma |
| NCT05261269 | Phase 1 | Feb 2, 2022 | Dantari, Inc. |
| NCT04669002 | Phase 2 | Dec 14, 2020 | Ellipses Pharma |
| NCT02457273 | Phase 2 | Jun 1, 2015 | Chang Gung University, Government of Taiwan, National Cheng Kung University, National Taiwan University, Taichung Veterans General Hospital, Taipei Veteran General hospital |
| NCT00492141 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2006 | University of Texas at Houston |
| NCT00333502 | Phase 1/Phase 2 (Phase 2) | May 1, 2006 | City of Hope National Medical Center, HonorHealth Research Institute, NewLink Genetics Inc, San Juan Oncology Associates |
| NCT00291837 | Phase 2 | Nov 1, 2004 | CTI BioPharma, Newcastle University |
| NCT00291785 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2004 | Catholic University of Sacred Heart, Rome, CTI BioPharma |
| NCT00250120 | Phase 2 | Apr 1, 2003 | University of New Mexico |
| NCT00059917 | Phase 1 | Jan 1, 2003 | Cornell University, National Cancer Institute (NCI) |
| NCT00040989 | Phase 2 | Jul 8, 2002 | National Cancer Institute (NCI), University of California, Los Angeles |